G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. (Q53485275)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 April 2007

edit

Language	Label	Description	Also known as
English	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.	scientific article published on 24 April 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

title

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

main subject

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author

Andrew M Evens

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Leo Gordon

series ordinal

14

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Martin S. Tallman

series ordinal

11

object named as

Martin S Tallman

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

Mrinal Gounder

series ordinal

4

object named as

Mrinal Gounder

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

author name string

Jeffrey Cilley

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Taylor Ortiz

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Nanjiang Hou

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Alfred Rademaker

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Sarah Miyata

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Kara Catsaros

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Connie Augustyniak

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Charles L Bennett

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Daina Variakojis

series ordinal

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

Jane N Winter

series ordinal

13

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

language of work or name

English

0 references

publication date

24 April 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

published in

British Journal of Haematology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

volume

137

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

page(s)

545-552

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

cites work

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Hodgkin's disease in adults in Saudi Arabia. Clinical features, prognostic factors and an analysis of therapy. Outcome of combination chemotherapy only, for both localized and advanced disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Bleomycin-induced pneumonitis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06598.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1365-2141.2007.06598.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

PubMed publication ID

17459049

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17459049

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/17459049

ResearchGate publication ID

6370237

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53485275&oldid=2101083316"